Search

Almac Diagnostic Services can also help Biopharma clients validate reliable Pharmacodynamic (PD) Biomarker assays that can help provide invaluable guidance within their drug development programs. Almac also has extensive experience in the discovery of clinically applicable biomarkers, through our own range of Almac proprietary assays (DDIR, Prostate Dx, ColDx, Angio, and EMT) and through developing biomarkers for our partners. […]

Clinical Support Almac Diagnostic Services has a dedicated medical team of 14 staff led by Professor Richard Kennedy, Global VP and Medical Director. Professor Kennedy is GMC registered and a Fellow of the Royal College of Physicians. He is registered under CLIA, CAP and CLEP as a medical lab director. (1) Clinical Testing Almac can […]

Almac’s Prognostic Assay for Intermediate Risk Prostate Cancer This 70 gene assay can prospectively identify patients at high risk of disease recurrence and/or metastasis following radical treatment. It is suitable for patients presenting with intermediate risk localized prostate cancer and should be used in conjunction with conventional risk factors or nomograms e.g. CAPRA-S/CAPRA to provide […]

Craigavon, N.I., 20 April 2017 – Almac Group’s Diagnostic Services business unit today announced the Journal of European Urology has published results relating to its Prostate Cancer Metastatic Assay. The publication demonstrates the assay can be used to analyze primary prostate cancer FFPE samples to identify a molecular subgroup with a high risk of developing […]

Queen’s University Belfast have led the world’s largest research study using a diagnostic test developed by Almac Diagnostic Services, to better understand the biology of prostate cancer tumors, which could lead to a transformation in how prostate cancer is diagnosed and treated. Whether a prostate cancer patient has a slow-growing or aggressive tumor will affect […]